A. Keith Stewart

Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome

N. Jewel Samadder, Douglas L. Riegert‐Johnson, Lisa A. Boardman et al. · JAMA Oncology · 2020 · 279 citations · Full text

Purging of Autologous Peripheral-Blood Stem Cells Using CD34 Selection Does Not Improve Overall or Progression-Free Survival After High-Dose Chemotherapy for Multiple Myeloma: Results of a Multicenter Randomized Controlled Trial

A. Keith Stewart, Robert Vescio, Gary J. Schiller et al. · Journal of Clinical Oncology · 2001 · 198 citations

Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.

Robert Vescio, Gary J. Schiller, A. Keith Stewart et al. · PubMed · 1999 · 172 citations

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

Donna Reece, Dan M. Sullivan, Sagar Lonial et al. · Cancer Chemotherapy and Pharmacology · 2010 · 106 citations · Full text

Hematological Malignancy, Pharmacodynamic Study, Oncology +6

Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.

EC LaCasse, Mark R. Bray, Bruce Patterson et al. · PubMed · 1999 · 101 citations